Form 4: LifeStance Health Group Officer Sells 150,000 Shares Under 10b5-1 Plan

Danish J. Qureshi, President and COO of LifeStance Health Group, sold 150,000 shares of common stock at a price of $5.2101 per share on June 14, 2024, under a pre-planned trading plan.

Summary

• On June 14, 2024, Danish J. Qureshi, the President and Chief Operating Officer of LifeStance Health Group, sold 150,000 shares of the company's common stock.
• The sale was executed at a price of $5.2101 per share.
• The transaction was conducted under a pre-planned trading plan adopted on March 15, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
• Following the transaction, Qureshi directly owns 4,827,941 shares and indirectly owns 589,002 shares through each of eleven different LLCs.
• Qureshi disclaims beneficial ownership of the shares held by the LLCs, except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine transaction (insider sale under a pre-planned trading plan). There is no indication of positive or negative implications for the company's performance.

Industry Context

Insider sales are a common occurrence, and this sale appears to be conducted under a pre-planned trading plan, which is a legal and transparent way for insiders to sell shares.

Comparison to Industry Standards

• Comparing this transaction to other healthcare companies, insider sales are a regular part of executive compensation and portfolio management.
• For example, executives at companies like Teladoc Health or Amwell also periodically sell shares, often under similar 10b5-1 plans.
• The size of the sale (150,000 shares) is not unusual for an officer-level executive at a company of LifeStance's size.

Stakeholder Impact

• The sale of shares by an officer could be perceived negatively by some shareholders, but the existence of a pre-planned trading plan mitigates this concern.

Key Dates